Intratympanic gentamicin for the treatment of Ménière's disease and other forms of peripheral vertigo

Research output: Contribution to journalReview article

Abstract

Titration therapy with intratympanic gentamicin offers class A or B control of vertigo in 87% (range, 75%-100%) of patients with unilateral Ménière's disease. The risk of additional hearing loss is about 21% (range, 0-37%) [22]. Vertigo may recur, however, in nearly one third of patients over time. These recurrences can also be treated by intratympanic gentamicin with a similar risk of hearing loss. The salient effect of intratympanic gentamicin is probably the reduction of vestibular function through damage to hair cells, but a complete ablation of function does not seem to be necessary for vertigo control.

Original languageEnglish (US)
Pages (from-to)1075-1090
Number of pages16
JournalOtolaryngologic Clinics of North America
Volume37
Issue number5
DOIs
StatePublished - Oct 1 2004

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'Intratympanic gentamicin for the treatment of Ménière's disease and other forms of peripheral vertigo'. Together they form a unique fingerprint.

  • Cite this